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Abstract
Aims: Sepsis is a cluster of heterogeneous syndromes associated with progressive endotoxemic 
developments, ultimately leading to damage of multiple organs, including the heart. However, the 
pathogenesis of sepsis-induced myocardial dysfunction is still not fully understood. The present study is the 
first to examine alterations in expression of key angiogenic signaling system mediated by vascular 
endothelial growth factor (VEGF) in septic heart and the effects of endothelin dual blocker (ETDB) on it.
Main methods: Normal Wistar rats were either administered with: a) vehicle only (control group), b) 
lipopolysaccharide only (LPS: 15 mg/kg) and then sacrificed at different time points (1 h, 3 h, 6 h and 10 h), 
and c) the last group was co-administered with LPS and ETDB (SB-209670, 1 mg/kg body weight) for 6 h 
and then sacrificed. Key findings: Administration of LPS resulted in increases in levels of: a) serum tumor 
necrosis factor (TNF)-α, serum VEGF and c) serum endothelin (ET)-1 levels accompanied by up-regulation 
of cardiac VEGF and its downstream angiogenic signaling molecules. While cardiac TNF-α level was 
unchanged among experimental groups, cardiac ET-1 level was significantly higher in LPS-administered 
group.
Significance: We conclude that elevation in VEGF angiogenic signaling may be triggered by diminished 
oxygenation in the myocardium following LPS administration as a consequence of sepsis-induced 
microvascular dysfunction. Because of this cardiac dysfunction, oxygen supply may be inadequate at 
microregional level to support the normal heart metabolism and function. ETDB at 6 h further increased 
the elevated levels of VEGF angiogenic signaling in endotoxemic heart.
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Vascular endothelial growth factor (VEGF), an endothelial cell-specific
mitogen that is important in neovascularization under both physiological
and pathophysiological conditions, plays a crucial role in blood vessel for-
mation during development and also in the regulation of hypoxia-
induced tissue angiogenesis (Banai et al., 1994a; Ferrara and Davis-
Smyth, 1997). VEGF possibly exerts these biological processes through
three mechanisms of action, namely by: (1) increasing blood flow to
the tissue via vasodilation, (2) reducing the distance between the cells
in the tissue and the nearest blood vessel by stimulating angiogenesis
and (3) increasing the permeability of the blood vessels to plasma,
small solutes and macromolecules. VEGF is a unique molecule in that is
up-regulated in all known endogenous physiological and pathological
forms of angiogenesis, can stimulate angiogenesis directly (Ferrara and
Bunting, 1996), is a potent vasodilator (Ku et al., 1993) and is able to in-
crease vascular permeability (Bates and Curry, 1996). In the normal
heart, the growth of new blood vessels is a rare occurrence, however,
chronic ischemiamay stimulate VEGF synthesis resulting in angiogenesis
and coronary collateral formation (Banai et al., 1994b; Sabri et al., 1991).
Endothelin (ET)-1, the most potent vasoconstrictor peptide known
to date (Mitaka et al., 1993; Yanagisawa et al., 1988) has been shown
to be significantly higher in plasma of septic patients (Battistini et al.,
1996) and a clear correlation exists among ET plasma levels, morbidity
andmortality in septic patients, a fact that suggests involvement of ET in
human septic shock (Pittet et al., 1991; Weitzberg et al., 1991). Further,
ET has been suggested to contribute to dysfunction of several vital organ
systems in septic shock.
In the present study, we intended to investigatewhether LPS admin-
istration in rat causes any changes in myocardial VEGF system expres-
sion and whether blockade of ET could have any effect on altered
VEGF system in the heart in sepsis.
Materials and methods
Animal preparation
Male Wistar rats (200–250 g, 8 weeks old) were used in all experi-
ments described in the present study. Endotoxemia was induced by ad-
ministering bacterial LPS (Escherichia coli 055: B5) (15 mg/kg in sterile
saline) intra-peritoneally (IP), a dose that was sufficient to induce
heart injury, as well as trigger an inflammatory cytokine response. The
control group (n= 26) received an equal volume of vehicle (sterile sa-
line; 2 ml/bodyweight), without LPS. And the rats received rehydration
therapy during the endotoxemia induction.
These animals were killed by Nembutal (sodium pentobarbital, IP,
80 mg/kg/body weight) at specific time points after treatment (LPS or
vehicle only), namely, 1, 3, 6, and 10 h post-treatments (n = 22 for
each time point). The blood samples were collected by cardiac puncture
for blood gas analysis, and heart tissues were harvested with care, snap
frozen in liquid nitrogen, and stored at −80 °C. All animal care proce-
dures were in compliance with the institutional guidelines, and the
experiments performed were approved by the Ethics Committee of
the Animal Resource Centre of the University of Tsukuba. In the second
part of the study, we investigated whether ET plays a specific role in the
pathogenesis of endotoxin using a LPS-induced endotoxemic rat model
administeredwith the dual ET antagonist (SB-209670) (GlaxoSmithKline
plc. GreatWest Road, Brentford,Middlesex, TW8 9GS, United Kingdom).
SB-209670 [(+)-(1S, 2R, 3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-
1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic
acid] is a non-peptide ET receptor antagonist which was rationally
designed using conformational models of a natural ligand, ET-1. SB-
209670 is one of the most potent ET receptor antagonist identified to
date and has been used to elucidate a role for ET as a mediator of cardio-
vascular pathophysiology (Ohlstein et al., 1994). Prior to treatments,
rats were anesthetized with urethane [35% ethyl carbamate (Wako
Pure Chemical Industries, Osaka, Japan) +4% alpha-chloralose (Wako)
saline wt./vol., 0.4 to 0.8 g/kg, IP], and the left jugular vein wascannulated for drug (LPS, dual ET antagonist) administration. All drugs
were administered intravenously as a slow bolus injection. Based on
our previous and pilot studies, the LPS-only treated group (15 mg/kg, in-
travenous) was killed 6 h after treatment.
Lastly, the dual ET blocker group was first treated with the blocker
(SB-209670) followed by LPS 15 min after the dual ET blocker was
administered intravenously (15 mg/kg in saline). After LPS administra-
tion, dual ET blocker was continuously infused (1 mg/kg/h) through the
jugular vein with a pump for 6 h (n = 18) for each group. Vehicle only-
treated rats were used as a control.
Measurements of hemodynamic parameters
The rats were anesthetized with Nembutal (40 mg/kg/body weight,
IP) and amicrotip pressure transducer catheter (SPC-320, Millar Instru-
ments, Houston, TX, USA)was inserted into the left carotid artery, as de-
scribed in our previous study (Jesmin et al., 2007; Sakai et al., 1996).
Then arterial blood pressure and heart rate were monitored with a
pressure transducer (model SCK-590, Gould, Ohio, USA) and recorded
with the use of a polygraph system (amplifier, AP-601 G, NihonKohden,
Tokyo, Japan; Tachometer, AT-601 G, Nihon Kohden; and thermal-pen
recorder, WT-687 G, Nihon Kohden).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA), a sensitive technique for
determining tissue protein concentration, was used to determine levels of
VEGF, endothelial nitric oxide synthase (eNOS) and tumor necrosis factor
(TNF)-α (R&D Systems, MN, USA) in heart tissues and in serum.
Enzyme-linked immunosorbent assay for plasma and cardiac ET-1 levels
Concentration of ET-1 in plasma and heart tissue extracts was deter-
mined using a Quantikine ET-1 Enzyme Immuno Assay Kit (R&D
Systems, MN, USA), according to the manufacturer's protocol. A 4.5 h
solid phase ELISA was used, and contained synthetic ET-1 and antibod-
ies raised against synthetic ET-1. This immunoassay has been shown to
accurately quantitate synthetic and naturally occurring ET-1. A mono-
clonal antibody specific for ET-1 was pre-coated onto a microplate.
Standards and samples were pipetted into the wells and if present,
ET-1 antigen was bound by the immobilized antibody. After washing
away any unbound substances, an enzyme-linkedmonoclonal antibody
specific to ET-1was added to thewells. Following awash to remove any
unbound antibody–enzyme reagent, a substrate solution was added to
the wells and a color developed in proportion to the amount of ET-1
bound in the initial step. The color development was then stopped
and its intensity measured. The ET-1 concentration of each sample
was calculatedwith a standard curve constructed by plotting the absor-
bance of each standard solution.
Nitric oxide colorimetric assay
Nitric oxide (NO) was indirectly detected in cardiac tissue extracts as
nitrite using a NO Colorimetric Assay kit (Roche Diagnostics, Mannheim,
Germany). In this method, the nitrate present in the sample was reduced
to nitrite by reduced nicotinamide adenine dinucleotide phosphate in the
presence of the enzyme nitrate reductase. The nitrite formed reacted with
sulfanilamide and N-(1-naphthyl)ethylenediamine dihydrochloride to
give a red-violet diazo dye. The diazo dye was measured at 550 nm, on
the basis of its absorbance within the visible range.
Statistical analysis
The results were expressed as mean ± SE, and the means were
compared by a one-way factorial analysis of variance, followed by
Tukey's or Bonferroni for multiple comparisons. For nonparametric
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Fig. 1. Expression levels of tumor necrosis factor-α (TNF-α; A), vascular endothelial
growth factor (VEGF; B) and endothelin-1 (ET-1; C) in serum or plasma from control
rats, lipopolysaccharide-administered (LPS) rats and LPS-administered rats treated with
dual endothelin blocker (LPS + ETDB). White bars, control subjects; gray bars, LPS-
administered rats; black bars, LPS + ETDB treated rats. Values are mean ± SE. *p b 0.05
vs. control; **p b 0.01 vs. control; #p b 0.05 vs. LPS; ##p b 0.01 vs. LPS.statistical analysis, the Kruskal–Wallis test was performed. Differences
were considered significant at p b 0.05. The statistical analysis and
calculations were performed using the SPSS 21.0 software package
(SPSS, Inc., Chicago, IL, USA).
Results
Blood gas and hemodynamic parameters (Table 1)
Arterial PaO2 was found to be significantly (p b 0.041) decreased
in LPS administered rats. However, arterial PaO2 increased remarkably
(p b 0.027) following SB-209670 injection in endotoxemic rats.
Blood lactate concentrations were increased dramatically after LPS
(p b 0.035) was given and increased (p b 0.027) further after SB-
90670 treatment in septic rats. Base excess was markedly (p b 0.042)
lowered in LPS administered group compared to control group.
Both the systolic and diastolic blood pressures significantly decreased
(p b 0.002) in LPS administered rats at 6 h compared to the control
rats. Heart rate was significantly higher (p b 0.025) in LPS administered
rats compared to the control rats and treatmentwith SB-209670 had no
significant effect on this elevated heart rate in endotoxemic rats.
Expression of TNF-α, VEGF and ET-1 in serum and plasma
Serum TNF-α level in rat administered with LPS was significantly
(p b 0.001) elevated compared to the control group and decreased
sharply (p b 0.013) following administration of dual ET blocker
(Fig. 1A). Consistent with our previous studies, serum VEGF levels in
the present study increased (p b 0.008) after LPS administration in
the endotoxemic rat model and was unchanged following the treat-
ment of the ET blocker (Fig. 1B). The plasma level of ET-1 (Fig. 1C)
was significantly higher (p b 0.003) in LPS administered group com-
pared to the control group andwas further up-regulatedwith the block-
ade of ET receptors.
Expression of cardiac VEGF, eNOS and NO levels
VEGF and eNOS/NO-related pathway promotes angiogenesis via
activation of an angiogenic signaling cascade. VEGF, which is consid-
ered the most potent angiogenic growth factor for the heart tissue,
appeared to be significantly elevated (p b 0.004) in the heart of the
LPS-administered endotoxemic rat, and was (VEGF) further elevated
(p b 0.025) after animals were treated with ET blocker (Fig. 2A). Con-
sistent with VEGF expression, levels of cardiac eNOS (Fig. 2B) were
found to be higher (p b 0.004) in LPS-administrated rats compared
to control group and increased further after treatment with ET
blocker, as demonstrated by ELISA analysis. Although concentrationTable 1
Effects of LPS on arterial blood gas and hemodynamic parameters.
Control LPS LPS + SB-209670
pH 7.45 ± 0.02 7.49 ± 0.02 7.44 ± 0.02
PaCO2 (mm Hg) 34.1 ± 3.4 26.4 ± 1.3 28.3 ± 4.5
PaO2 (mm Hg) 100.9 ± 3.5 87.2 ± 3.7⁎ 105.4 ± 4.1#
HCO3− (mmol/l) 23.1 ± 1.46 20.0 ± 0.89 19.3 ± 2.77
Base excess (mmol/l) −0.2 ± 1.1 −3.7 ± 1.0⁎ −5.1 ± 2.8
Lactate (mmol/l) 0.6 ± 0.2 1.7 ± 0.2⁎ 1.9 ± 0.5⁎
Systolic BP (mm Hg) 128 ± 5.75 89 ± 4.43⁎⁎ 91 ± 4.60⁎⁎
Diastolic BP (mm Hg) 97 ± 6.28 75 ± 3.13⁎ 73 ± 2.03⁎⁎
HR (bpm) 432 ± 17.5 492 ± 8.56⁎⁎ 470 ± 7.75
Abbreviations: systolic BP, systolic blood pressure; diastolic BP, diastolic blood pressure;
HR, heart rate; LPS, lipopolysaccharide.
Data are mean ± SE.
⁎ p b 0.05 vs. control.
⁎⁎ p b 0.01 vs. control.
# p b 0.05 vs. LPS.of NO, which is the final downstream molecule of VEGF angiogenic
signaling, was significantly increased (p b 0.046) in the heart of the
endotoxemic rat, ET blocker failed to further induce increase in the
concentration of cardiac NO in LPS-treated group, implying the pres-
ence of a non-functional and disrupted VEGF angiogenic signaling in
ET blocker-treated heart (Fig. 2C).
Expression of cardiac TNF-α and ET-1 levels
In all the three experimental groups, cardiac levels of TNF-α level
were statistically found to be similar (Fig. 3A). However, levels of cardi-
ac ET-1 were found to be significantly up-regulated (p b 0.008) in LPS-
administered rats and were further up-regulated (p b 0.005) following
treatment with ET blocker (Fig. 3B).
Discussion
The key findings of the present study are that: 1) the components of
VEGF angiogenic signaling are significantly up-regulated in the heart at
6 h after LPS administration; and 2) dual blockade of ET action for 6 h
exacerbates components of the up-regulated VEGF angiogenesis signal-
ing system in cardiac tissues of the endotoxemic rats.
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Fig. 2. Expression levels of components of vascular endothelial growth factor (VEGF)
angiogenic signaling pathway in cardiac tissues as demonstrated by ELISA: protein expres-
sion levels of VEGF (A), endothelial nitric oxide synthase (eNOS) (B) and nitric oxide (NO)
(C) in heart tissues obtained from control rats, lipopolysaccharide-administered (LPS) rats
and LPS-administered rats treated with dual endothelin blocker (LPS + ETDB). White
bars, control subjects; gray bars, LPS-administered rats; black bars, LPS + ETDB treated
rats. Values are mean ± SE. *p b 0.05 vs. control; **p b 0.01 vs. control; #p b 0.05 vs. LPS.
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Fig. 3. Expression levels of tumor necrosis factor-α (TNF-α) and endothelin-1 (ET-1)
in the cardiac tissues, as revealed by ELISA: protein expression levels of TNF-α (A) and
ET-1 (B) in heart tissues obtained from control rats, lipopolysaccharide-administered
(LPS) rats and LPS-administered rats treated with dual endothelin blocker (LPS + ETDB).
White bars, control subjects; gray bars, LPS-administered rats; black bars, LPS + ETDB
treated rats. Values are mean ± SE. **p b 0.01 vs. control; ##p b 0.01 vs. LPS.Inadequate oxygen supply is probably themost important pathophys-
iological mechanism that leads to myocardial dysfunction (Jurgensen
et al., 2004). It (low oxygen concentration) may also play an important
role in sepsis pathophysiology and subsequent decrease in heart function.
Specifically, progressive hypoxia reduces left ventricle contractility
(Walley et al., 1988). Although direct evidence of tissue hypoxia within
the septic heart has been lacking (Avontuur et al., 1995; Herbertson
et al., 1995; Hotchkiss et al., 1991) evidence showing diminished blood
flow via autoregulation (Avontuur et al., 1997), as well as loss of myocar-
dial capillary density (Barroso-Aranda et al., 1991), suggests disruption of
capillary blood flow (Ellis et al., 2002) in the septic heart and overall
compromise of microvascular oxygen transport (Bateman et al., 2003).
Because of sepsis-induced microvascular dysfunction, oxygen supply
may be inadequate to support normal heart metabolism and function.
Physical stress, ischemia or infection induces a remodeling process of
the cardiovascular system through activation of cardiac myocytes, fibro-
blasts, endothelial cells, and smooth muscle cells. Locally expressed
growth factors including platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF) and VEGF are known to play key roles
in these processes. It is very likely that the heart of the endotoxemic ratin the present study might have been hypoxic, which in turn could
have enhanced the expression of VEGF in the cardiac tissues following
LPS administration. Such a speculation is consistent with data from a
recent study that demonstrated that HIF-1α expression is up-regulated
in a heart of an endotoxemic rat, 5 h post-LPS administration (Bateman
et al., 2007). Another important downstream molecule of VEGF angio-
genic signaling that was found to be up-regulated in the present study,
following LPS administration, was eNOS. At the local level, the microcir-
culation regulates and distributes red blood cells and oxygen throughout
the tissue tomaintain tissue oxygen concentration (Bateman et al., 2003).
However, despite normal or enhanced cardiac output during sepsis,
distribution and regulation of local tissue oxygen delivery are compro-
mised by decreased functional capillary density (Bateman et al., 2001;
Boczkowski et al., 1992; Goldman et al., 2004; Lam et al., 1994) and
diminished microvascular vasoconstriction (McKinnon et al., 2006). Al-
though we show here that levels of cardiac NO, the final downstream
molecule of VEGF angiogenic signaling, increase after LPS administration,
for nowwe are unclear on the source of the up-regulated NO, i.e., wheth-
er it is from eNOS or iNOS, or the state of its biological activity. Thus, we
suggest that in the heart of an endotoxemic rat, both VEGF and its down-
stream molecule eNOS, are up-regulated by hypoxia. However, because
of the absence of a functionally active NO in the heart, the up-regulated
VEGF angiogenic signaling could not correct the compromised coronary
microcirculation in endotoxemia.
Another important finding of the present study is the data showing
that dual blockade of ET further up-regulated the already high levels
of VEGF angiogenic signaling molecules. The key role played by ET in
the pathogenesis of sepsis has been adequately described previously.
Endotoxins increase plasma ET-1 levels, along with increased mRNA
expression of preproET-1 in the lungs and heart (Hemsen, 1991;
Kaddoura et al., 1996). Experiments involving infusion of ET-1 show
signs of cardiovascular complications generally associated with septic
shock (Weitzberg et al., 1991, 1993), suggesting that ET mechanisms
may be the central factor behind the dysfunction of vital organs during
sepsis (Oldner et al., 1999; Pittet et al., 1991). Consistent with these
earlier findings, here we show that plasma and cardiac ET-1 levels are
significantly higher in the LPS-induced endotoxemic rat model. Further
up-regulation of cardiac ET-1 level in the heart of LPS-administered rat
with the treatment of dual ET blocker suggests that effective ET block-
ade has been achieved in the present study. Overexpression of cardiac
ET-1 triggers an increase in inflammatory cytokines, such as TNF-α, IL-
1, and IL-6, as well as interstitial inflammatory infiltration and an
inflammatory cardiomyopathy that subsequently leads to heart failure
and death (Shindo et al., 1998). Here, serum TNF-α levels in LPS-
administrated rats were significantly elevated compared to control
group andwere remarkably decreased by dual blockade of ET. However,
in the present study, we could not observe a parallel relationship
between the expression of cardiac ET-1 and TNF-α. TNF-α is also capa-
ble of inducing gene expression of the pro-angiogenic molecules, such
as VEGF and its receptors (VEGFRs) (Giraudo et al., 1998; Ristimaki
et al., 1998). However, the pattern of TNF-α and VEGF expression was
reversed in the heart of an endotoxemic rat. Although the reverse rela-
tionship between cardiac VEGF and TNF-α cannot be adequately
explained at present, we have reported similar data previously
(Jesmin et al., 2012) using a LPS-induced lung injury model. In LPS-
induced lung injury model, we demonstrated a time-dependent
decrease in VEGF expression in pulmonary tissue compared to that of
control rats. In contrast, pulmonary levels of TNF-α showed a significant
up-regulation up to the 3 h time point and then returned to almost con-
trol levels at 6 h and 10 h after LPS administration (Jesmin et al., 2012).
Indeed, reverse relationships that have been described before between
TNF-α and VEGF receptors (Patterson et al. 1996). Patterson et al.
(1996) have demonstrated that TNF-α is capable of significant anti-
angiogenic activity bymodulating VEGF receptor expression in cultured
human vascular endothelial cells. TNF-α is widely accepted as the
central proinflammatory cytokine mediating cellular responses to both
endogenous and exogenous stimuli. Although responsible for signifi-
cant VEGF release from a myriad of cell types, it's (TNF-α) primary
effects in high concentrations (as occurs in infection and malignancy)
is anti-angiogenic (Patterson et al., 1996). Thus, high local or circulating
levels of TNF-αmay, in part, attenuate tissue repair by causing function-
al down-regulation of VEGF receptors on endothelial cells in these cir-
cumstances. But the reverse relationship between cardiac VEGF and
TNF-α observed in the present study, as well as our previous study
(Jesmin et al., 2012), needs further studies for more clarification.
The interaction between VEGF and ET-1 in vascular endothelial and
smooth muscle cells is well documented. ET-1 has been documented to
enhance VEGF mRNA expression via activation of ETA receptors in rat
vascular smooth muscle cells (Matsuura et al., 1998). ET-1 and VEGF
apparently play a complementary and coordinated role during neovas-
cularization and malignant ascites formation in ovarian carcinoma
(Salani et al., 2000a). The endothelial autocrine regulatory role of ET-
1, as a putative angiogenic factor in the process of neovascularization,
has been recently reported (Salani et al., 2000b). In contrast with
those reports, ET receptor blockade with bosentan shows a marked
pro-angiogenic effect in an ischemic leg after femoral occlusion, and
this effect appears to be directly dependent on the VEGF/eNOS path-
ways (Iglarz et al., 2001). Bosentan was considered to modulate
ischemia-induced angiogenesis by increasing the speed of revasculari-
zation and maintaining sustained activation of the process (Iglarz
et al., 2001). However, several lines of evidence suggest cell mitogen
and proliferating effects of ET-1 in in vitro studies (Hirata et al., 1989;
Wren et al., 1993; Yang et al., 1999). We clearly demonstrate that ET
receptor blockadewith SB-209670 exacerbates cardiacVEGF angiogenic
signaling in endotoxemia. In sepsis, plural stimuli may be involved
in the angiogenic response, depending on the tissue type or organinvestigated. Future studies should aim to shedmore light on themech-
anisms underlying the further up-regulation of VEGF signaling by ET
receptor antagonism in sepsis.
Besides, the effects of SB-209670 on the up-regulated VEGF signaling
cascade in endotoxemic heart as observed in the present study, SB-
209670 did not exert any effect on pH and lactate levels. On the other
hand, Andersson et al. (2008) demonstrated improved pH and arterial
lactate values using tezosentan. For now, we cannot fully account for
this discrepancy. Study designs, including the types of ET blocker used,
treatment duration, and types of experimental animals used, might be
responsible for such discrepancy between the present study and the
study by Andersson et al. (2008).
One of the important limitations of the present study is that we
did not investigate the effects of using a long term treatment period
for SB-209670 and the subsequent effects on cardiac VEGF signaling
in endotoxemic rats. In our unpublished observation we found that
VEGF did not show any clear time-dependent expression profile in
endotoxemic heart. To the contrary, a biphasic pattern has been ob-
served (Oki et al., unpublished observation, 2013). Thus, future studies
should carefully examine the effects, if any, of long term SB-209670
treatment on VEGF signaling in an endotoxemic rat heart and the in
depth investigations should address the observed effects of SB-209670
in the hearts for both hemodynamic compensatory and decompensatory
phases of sepsis. Lastly, the present study could not clarify the role of
blood pressure in the observed effects of cardiac VEGF signaling by SB-
209670 in endotoxemic rat heart, thus warranting further studies.
Conclusion
The up-regulation of VEGF angiogenic signaling as observed in the
present study may be due to diminished oxygenation of myocardium
in LPS-administered rats, as a consequence of sepsis-induced microvas-
cular dysfunction, implying that oxygen supply may have been inade-
quate at the local level to support normal heart metabolism and
function. Dual blockade of ET for 6 h further elevated the VEGF angio-
genic signaling in endotoxemic heart.
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